Top Markets
Coin of the day
Organicell Regenerative Medicine, Inc. Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc.

OCEL
株式のランク #31539
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical... Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.
株価
$1.77
最終同期: 2024-04-02
時価総額
$12.89M
変化(1日)
-11.50%
変化(1年)
0.00%
US
取引 Organicell Regenerative Medicine, Inc. (OCEL)

カテゴリー

Organicell Regenerative Medicine, Inc.(OCEL)のEPS
2026 時点のEPS TTM: 0
Organicell Regenerative Medicine, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Organicell Regenerative Medicine, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS